For most of the drugs advantages of taking medications overweighs the potential risks however some drugs could be really dangerous for breastfed baby hence every medication shall be considered separately. In this page we will discuss about purpose of Isoniazid Tablet and its risk associated with lactation. We will also discuss the usage of Isoniazid Tablet and some common side effects associated with Isoniazid Tablet.
What is Isoniazid Tablet used for?
Isoniazid tablets are recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy. Isoniazid tablets are recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): 1.Persons with human immunodeficiency virus (HIV) infection (greater than or equal to 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. 2.Close contacts of persons with newly diagnosed infectious tuberculosis (greater than or equal to 5 mm). In addition, tuberculin-negative (less than 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (greater than 5 mm), therapy should be continued. 3.Recent converters, as indicated by a tuberculin skin test (greater than or equal to 10 mm increase within a 2-year period for those less than 35 years old; greater than or equal to 15 mm increase for those greater than or equal to 35 years of age). All infants and children younger than 4 years of age with a greater than 10 mm skin test are included in this category. 4.Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (greater than or equal to 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. 5. Intravenous drug users known to be HIV-seronegative (greater than 10 mm). 6.Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (greater than or equal to 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin’s disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state [with or without weight loss], chronic peptic ulcer disease, chronic malabsorption syndromes and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: 1.Foreign-born persons from high-prevalence countries who never received BCG vaccine. 2.Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics and Native Americans. 3.Residents of facilities for long-term care (e.g., correctional institutions, nursing homes and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have greater than 10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1 to 6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1 to 6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected.
Is Isoniazid Tablet usage safe while breastfeeding? If a lactating mother is using it can there be any effect on growth or development of infant?
Isoniazid is the only one ingredient used in manufacturing of Isoniazid Tablet, Which makes it easier to analyze its effect in breastfeeding. As per our analysis of Isoniazid it is safe to use Isoniazid Tablet while lactating. We suggest you to check further details below about Isoniazid usage in breastfeeding.
Statement of Manufacturer/Labeler about breastfeeding usage
Nursing Mothers The small concentrations of isoniazid in breast milk do not produce toxicity in the nursing newborn; therefore, breast feeding should not be discouraged. However, because levels of isoniazid are so low in breast milk, they cannot be relied upon for prophylaxis or therapy of nursing infants.
Isoniazid Tablet Breastfeeding Analsys
Isoniazid while Breastfeeding Safe
CAS Number: 54-85-3
It is excreted into breast milk in clinically non-significant amount, in any case, much lower than the doses commonly used in newborns and infants (Snider 1984, Singh 2008). No significant problems have been observed in infants whose mothers were treated. (Drobac 2005). An infant whose mother was treated with anti-TBC drugs during pregnancy and lactation for 7 months, presented moderately high levels of liver transaminases along with a normal clinical and developmental course (Peters 2008). The plasma levels measured in any of those infants were undetectable or very low. Several medical societies and consensus of expert panels consider safe the use of this medication while breastfeeding (Dautzenberg 1988, Tran 1998, Blumberg 2003, Schram 2005, WHO 2007, Singh 2008, Baquero-Artigao 2015, Malhamé 2016).American Academy of Pediatrics: medication usually compatible with breastfeeding.WHO List of Essential Medicines 2002: compatible with breastfeeding. The addition of Vitamin B6 (Pyridoxine) to treatment of mother-infant dyad should be evaluated, especially in cases of malnutrition, diabetes, other diseases or a new pregnancy (Blumberg 2003, Steichen 2006, Baquero-Artigao 2015, 2016 Principi Di 2016).
Isoniazid Tablet Breastfeeding Analsys - 2
Isoniazid while Breastfeeding
CAS Number: 54-85-3
The Centers for Disease Control and Prevention and other professional organizations state that breastfeeding should not be discouraged in women taking isoniazid. Nursing mothers who are taking isoniazid should take 25 mg of oral pyridoxine daily. Because of the low levels of isoniazid in breastmilk and safe administration directly to infants, it is unlikely to cause adverse reactions in infants, but infants should be monitored for rare instances jaundice. Giving the maternal once-daily dose before the infant's longest sleep period will decrease the dose the infant receives. The amount of isoniazid in milk is insufficient to treat tuberculosis in the breastfed infant. If breastfed infants are treated with isoniazid, they should also receive pyridoxine 1 mg/kg daily.
What should I do if I am breastfeeding mother and I am already exposed to Isoniazid Tablet?
As usage of Isoniazid Tablet is mostly safe while breastfeeding hence there should not be any concern. In case of any change in behavior or health of your baby you should inform your health care provider about usage of Isoniazid Tablet else no further action is required.
I am nursing mother and my doctor has suggested me to use Isoniazid Tablet, is it safe?
Definitely, Isoniazid Tablet is safe in lactation for baby. No wonder your doctor has recommended it.
If I am using Isoniazid Tablet, will my baby need extra monitoring?
No extra baby monitoring required while mother is using Isoniazid Tablet
Who can I talk to if I have questions about usage of Isoniazid Tablet in breastfeeding?
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week